PFAS in the Hudson Valley: A Review of Exposure Pathways, Health Endpoints, and Regulatory Gaps

1. Introduction

Per- and polyfluoroalkyl substances (PFAS) are a class of several thousand synthetic organofluorine compounds characterized by carbon–fluorine bonds, among the strongest single bonds in organic chemistry. That bond strength gives PFAS their industrial utility — heat resistance, oil and water repellency, surfactant behavior — and also their environmental persistence, which is the origin of the colloquial term "forever chemicals."

The Hudson Valley presents a distinctive exposure geography. The region combines legacy industrial manufacturing, military and civilian airfields with a documented history of aqueous film-forming foam (AFFF) use, a dense network of small groundwater-dependent public water systems and private wells, land application of biosolids on agricultural soils, and a growing footprint of warehouse and data-center development that alters stormwater conveyance. Each of these features maps onto a well-described PFAS source or transport pathway.

This review synthesizes the published literature on PFAS sources, environmental transport, human exposure pathways, and health endpoints, and evaluates the current federal and New York State regulatory framework against that evidence. It is written for a mixed audience of municipal officials, water-system operators, and residents, and is intended to support local decision-making rather than to advance a novel empirical finding.

2. Scope and method

This is a narrative literature review, not a primary-data study. Sources were identified through structured searches of PubMed, Web of Science, and agency document repositories (US EPA, ATSDR, NYSDOH, NYSDEC) for the period 2000–2026, using the search terms "PFAS," "PFOA," "PFOS," "perfluoroalkyl," combined with "drinking water," "biosolids," "AFFF," "serum," and "epidemiology."

Priority was given to (a) peer-reviewed epidemiological studies with measured serum concentrations, (b) systematic reviews and agency toxicological profiles, and (c) state and federal regulatory determinations with published technical support documents. Grey literature was included only where it reported primary monitoring data from regulated water systems. Studies limited to in vitro endpoints without a human or environmental exposure component were excluded except where cited to describe mechanism.

Limitations are substantial and stated up front. Most PFAS monitoring data are limited to a small number of legacy long-chain compounds; the analytical methods in routine regulatory use do not capture the majority of PFAS in commerce. Region-specific Hudson Valley data are sparse, and much of the exposure characterization below is extrapolated from studies conducted in structurally similar settings elsewhere in the Northeast.

3. Sources and environmental transport

Four source categories dominate the regional picture. First, fluorochemical and fluoropolymer manufacturing and downstream industrial users — textile finishing, metal plating, paper coating — release PFAS to air and to publicly owned treatment works, which are not designed to remove them. Second, AFFF used in firefighting training and in emergency response at airports, refineries, and military installations produces highly concentrated, spatially discrete groundwater plumes; this is the best-documented mechanism behind catastrophic drinking-water contamination in the Northeast.

Third, land application of municipal biosolids transfers PFAS accumulated in wastewater sludge onto agricultural soils, from which compounds can leach to shallow groundwater and be taken up by forage and food crops. Fourth, landfill leachate — including leachate from closed and unlined legacy sites — provides a persistent, long-duration release that often returns to a wastewater plant, creating a recirculating loop.

Transport behavior differs sharply by chain length. Long-chain compounds such as PFOA and PFOS sorb more strongly to organic carbon and partition into biota, producing elevated concentrations in fish tissue and in surface soils near source zones. Short-chain and ultrashort-chain replacements are substantially more mobile in groundwater, travel farther from source zones, and are poorly removed by conventional granular activated carbon, which is the treatment technology most municipalities have installed.

Development pattern matters here in a way that is often overlooked. Large impervious sites concentrate and accelerate stormwater, shortening residence time and reducing the natural attenuation available in vegetated buffers. Where such sites overlie or discharge toward shallow aquifers used for public supply, the effective distance between a source zone and a drinking-water intake is functionally reduced.

4. Human exposure pathways

Drinking water is the dominant exposure route in communities with a contaminated source, and it is the route most amenable to intervention. In communities without a point source, diet — particularly fish, meat, dairy, and food contacting fluorinated packaging — typically contributes a larger share of total intake.

Indoor exposure is non-trivial and frequently underestimated. House dust, treated carpets and upholstery, waterproofed apparel, and some cosmetics contribute measurable body burden, and the profile of compounds found indoors is often dominated by short-chain and precursor species that routine water monitoring does not measure.

Occupational and residential proximity effects are well described. Populations living near fluorochemical facilities show elevated serum concentrations relative to national reference values, and the magnitude of that elevation is a function of both distance and the specific environmental matrix — soil, private well, or garden produce — that mediates the exposure.

Body burden is durable. Serum elimination half-lives for PFOA and PFOS are measured in years, meaning that an exposure ending today produces a serum concentration that declines only slowly over a subsequent decade. This is the practical reason that source control, not behavior change, is the effective intervention.

5. Health endpoints

The evidence base is strongest for a set of endpoints repeatedly observed across independent cohorts. The Agency for Toxic Substances and Disease Registry's toxicological profile and subsequent reviews identify increased cholesterol, changes in liver enzymes, decreased infant birth weight, reduced vaccine antibody response in children, thyroid hormone disruption, pregnancy-induced hypertension and preeclampsia, and increased risk of kidney and testicular cancer.

Immunotoxicity deserves particular emphasis because it is observed at comparatively low serum concentrations and because the affected endpoint — antibody response following routine childhood immunization — is measurable, clinically meaningful, and consistent across studies conducted in different populations. Recent mechanistic work using human peripheral blood mononuclear cells reports PFAS-driven T-cell proliferation and immune dysregulation, providing biological plausibility for the epidemiological signal.

Two caveats apply. Nearly all epidemiological work characterizes exposure to a handful of legacy compounds, while real exposure is to complex mixtures; additivity is assumed rather than demonstrated. And because essentially the entire population is exposed, studies lack a true unexposed comparison group, which tends to bias effect estimates toward the null.

6. Regulatory framework and gaps

In April 2024 the US EPA finalized the first National Primary Drinking Water Regulation for PFAS, setting enforceable maximum contaminant levels of 4.0 parts per trillion for PFOA and PFOS individually, 10 parts per trillion for PFHxS, PFNA, and GenX chemicals, and a hazard-index approach for mixtures of PFHxS, PFNA, PFBS, and GenX. New York State had previously adopted 10 parts per trillion MCLs for PFOA and PFOS in 2020, among the earliest state standards in the country.

Three structural gaps persist. The regulation covers a small number of compounds out of thousands in commerce, which creates a regrettable-substitution dynamic in which regulated long-chain compounds are replaced by unregulated short-chain analogues of comparable persistence. Private wells — a substantial share of Hudson Valley households — are outside the drinking-water regulatory framework entirely and are tested only at the owner's initiative and expense. And no comparable enforceable standard governs PFAS in biosolids applied to agricultural land, in landfill leachate discharged to treatment works, or in most consumer products.

A defensible policy response therefore has to operate upstream of drinking-water treatment. Class-based regulation, restrictions on non-essential uses, mandatory characterization of biosolids before land application, and public funding for private-well testing all address the gap that a compound-by-compound MCL structurally cannot.

7. Recommendations for Hudson Valley municipalities

Systematically characterize source zones before designing treatment. Municipalities should inventory historical AFFF use sites, industrial dischargers, closed landfills, and biosolids application fields within source-water protection areas, and prioritize monitoring accordingly rather than sampling uniformly.

Test on the analyte list that matches the risk, not the minimum. Where budget allows, use methods that report short-chain and precursor compounds alongside the regulated list, so that treatment selection is not invalidated by breakthrough of compounds that were never measured.

Fund private-well testing as a public-health function. Owner-initiated testing systematically under-samples the households least able to pay for remediation, which converts a contamination problem into an equity problem.

Incorporate PFAS pathways into land-use review. Environmental review of large impervious developments should address stormwater residence time, aquifer vulnerability, and cumulative loading, not only peak-flow attenuation.

Support state-level class-based restriction. Local treatment expenditure is a permanent operating cost imposed on ratepayers by upstream production decisions; restriction at the point of manufacture is the only intervention that ends the cost.

8. Conclusion

PFAS contamination in the Hudson Valley is not a discrete event to be remediated but a chronic condition to be managed, driven by persistence, mobility, and continued production. The evidence supporting adverse human health effects at low serum concentrations is sufficient to justify precautionary action at the municipal level now, without waiting for compound-by-compound regulatory determinations that will lag production by decades.

The most consequential local actions are unglamorous: source-zone inventories, well testing, analytically adequate monitoring, and land-use review that treats groundwater as infrastructure. The most consequential state action is class-based restriction of non-essential uses. Both are achievable with existing authority.